At the European League Against Rheumatism Annual Congress (EULAR 2014), scientists presented the possibility of using biomarkers to predict disease outcomes at 12 months in children with juvenile idiopathic arthritis (JIA).

Study authors found that long-term disease status at 12 months was predicted only after treatment had been initiated. Baseline expression profiles can predict disease status at 6 months but by utilizing 4-month data, researchers were able to determine accurate predictive properties for disease status at 12 months.

RELATED: Arthritis Treatments: DMARDS and Other Immune Modulators

The study also revealed the different mechanisms of response in Rheumatoid Factor (RF) positive and RF negative patients after 4 months. These differences were a possible explanation for the refractory response of RF positive patients to standard effective therapies.

For more information visit